INTEGRATED THERAPEUTIC APPROACH TO PREVENT CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION
Abstract
This article analyzes the effectiveness of an integrated therapeutic approach in preventing cardiovascular complications in patients with type 2 diabetes mellitus (T2DM) and arterial hypertension (AH). Based on clinical observation, the efficacy of conventional treatment and modern integrated therapy—including SGLT2 inhibitors, RAAS blockers, and statins—was compared. The obtained results demonstrate that a comprehensive approach significantly reduces cardiovascular events [2][3], improves glycemic control, and enhances renal function [2]. This study may aid clinicians in selecting optimal therapeutic strategies for this patient population.
Keywords
Type 2 diabetes mellitus, arterial hypertension, cardiovascular complications, integrated therapy, SGLT2 inhibitors, RAAS blockers, glycemic control.
References
- Williams B, Mancia G, Spiering W, et al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J, 39(33):3021–3104.
- Zinman B, Wanner C, Lachin JM, et al. (2015). Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. NEJM, 373:2117–2128.
- Wiviott SD, Raz I, Bonaca MP, et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. NEJM, 380(4):347–357.
- Cannon CP, Blazing MA, Giugliano RP, et al. (2015). Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. NEJM, 372(25):2387–2397.
- Neal B, Perkovic V, Mahaffey KW, et al. (2017). Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. NEJM, 377(7):644–657.
- American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022. Diabetes Care, 45(Suppl 1):S1–S134.
- Bakris GL, Agarwal R, Anker SD, et al. (2020). Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. NEJM, 383(23):2219–2229.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. (2019). Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. NEJM, 381(21):1995–2008.